Physician profile
Michael Jesse
NPI 1538125885
$1,546.32
in general payments reported to CMS, 2019-2025
28 companies · $99.53 in 2025
The $99.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $310 · 2021: $103 · 2022: $64.91 · 2023: $466 · 2024: $127 · 2025: $99.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.88 | 2022-2025 | |
| Amgen INC. | $119.74 | 2019-2025 | Evenity |
| Lilly USA, LLC | $115.42 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $67.06 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $64.57 | 2020-2021 | |
| Cranial Technologies, INC | $58.77 | 2019-2025 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $56.05 | 2020-2022 | |
| Pfizer INC. | $50.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.44 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $39.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $38.73 | 2023-2024 | Bexsero, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $35.11 | 2020 | |
| Corium, LLC | $34.80 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $34.18 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Dexcom, INC. | $29.29 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $26.05 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $25.99 | 2021 | |
| Corcept Therapeutics | $25.14 | 2020 | |
| Shire North American Group INC | $22.30 | 2019 | |
| Allergan, INC. | $19.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.53 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.06 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.59 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.35 | 2020 | |
| Sobi, INC | $11.93 | 2019 | |
| Upsher-Smith Laboratories LLC | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.